CPRX Financial Facts
Total operating costs and expenses: 3.91MResearch and development: 2.49M
See Full Income Statement
Deficit accumulated during the development stage: -103.98M
Total liabilities: 2.41M
See Full Balance Sheet
Catalyst Pharmaceutical Partners Inc. (CPRX) Earnings
|
Expand Research on CPRX
| Next EPS Date | 5/7/24 | EPS Growth Rate | -46.3% |
|---|---|---|---|
| Average EPS % Beat Rate | +126.3% | Revenue Growth Rate | +16.4% |
| Average % Move 1-Wk after EPS | -1.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4/1/11 | Q111 | -$0.04 | -$0.07 | +$0.03 | N/A | N/A | N/A |  | | Details | |
5/16/11  |
Q111 | -$0.08 | N/A | N/A | N/A | N/A | N/A | | | Details | |
| 8/16/11 | Q211 | -$0.06 | N/A | N/A | N/A | N/A | N/A | | | Details | |
| 11/15/11 | Q311 | -$0.05 | -$0.07 | +$0.02 | N/A | N/A | N/A | | | Details | |
| 4/2/12 | Q411 | -$0.10 | -$0.06 | -$0.04 | N/A | N/A | N/A | | | Details | |
| 5/16/12 | Q112 | -$0.04 | -$0.08 | +$0.04 | N/A | N/A | N/A | | | Details | |
| 8/15/12 | Q212 | -$0.01 | -$0.05 | +$0.04 | N/A | N/A | N/A | | | Details | |
| 11/15/12 |
Q312 | -$0.08 | N/A | N/A | N/A | N/A | N/A | | | Details |
